Rigel Pharmaceuticals, Inc. (RIGL)

Market Cap	342.44M
Revenue (ttm)	203.08M
Net Income (ttm)	37.18M
Shares Out	17.87M
EPS (ttm)	2.08
PE Ratio	9.20
Forward PE	11.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	210,882
Open	20.12
Previous Close	n/a
Day's Range	19.14 - 20.39
52-Week Range	7.48 - 29.82
Beta	1.29
Analysts	Buy
Price Target	36.40 (+89.98%)
Earnings Date	Aug 5, 2025

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 29, 2000
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: RIGL
• Website: https://www.rigel.com

Analyst Forecast

According to 5 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is $36.4, which is an increase of 89.98% from the latest price.

Price Target

$36.4

(89.98% upside)

Analyst Consensus: Buy